Ishibashi F
Ishibashi Clinic, Hiroshima, Japan.
Diabetes. 1996 Jun;45(6):731-5. doi: 10.2337/diab.45.6.731.
After an intravenous infusion Of L-arginine to inhibit tubular reabsorption of albumin, glomerular clearance, renal clearance, and tubular reabsorption of unmodified albumin (UMA) and glycated albumin (GA) were determined in 72 patients with NIDDM without (NIDDM-I; n = 47) or with microalbuminuria (NIDDM-II; n = 25) and in 24 healthy control subjects. Samples of serum albumin and dialyzed urine obtained 60 min before and during L-arginine infusion were applied to an affinity column to separate GA from UMA, and their albumin contents were assayed. The serum level of GA in NIDDM patients was higher than that in control subjects (P < 0.0001). Both UMA and GA were excreted in excess in NIDDM-II as compared with the other two groups (P < 0.0001), and UMA comprised 80% of total albumin excretion. In NIDDM-II, the glomerular clearance of UMA (2.5 +/- 0.16 > NIDDM-I [1.8 +/- 0.1] > control subjects [1.3 +/- 0.1 microliter/min], P < 0.001) and of GA (1.7 +/- 0.13 > NIDDM-I = control subjects [1.1 +/- 0.1 microliter/min], P < 0.001) were enhanced, as compared with the other two groups. Renal clearance of UMA (1.3 +/- 0.13 microliter/min) and GA (0.89 +/- 0.09 microliter/min) in NIDDM-II was greater than that in control subjects (0.27 +/- 0.03, 0.19 +/- 0.02 microliter/min) or in NIDDM-I (0.30 +/- 0.03, 0.11 +/- 0.01 microliter/min). Tubular reabsorption of UMA, as assessed by the difference between glomerular and renal clearances of albumin, in NIDDM-II (1.1 +/- 0.1 microliter/min) was less than in NIDDM-I (1.50 +/- 0.09 microliter/min), and that of GA in NIDDM-II was lower than that in the other two groups, despite exaggerated glomerular clearance of GA and UMA in NIDDM-II. In summary, microalbuminuria in NIDDM is caused by increased excretion of UMA resulting from the decompensated ability of tubular reabsorption, which is exceeded by increased glomerular clearance of UMA.
对72例非胰岛素依赖型糖尿病(NIDDM)患者(其中无微量白蛋白尿的NIDDM - I组,n = 47;有微量白蛋白尿的NIDDM - II组,n = 25)以及24名健康对照者静脉输注L - 精氨酸以抑制肾小管对白蛋白的重吸收,然后测定肾小球清除率、肾清除率以及未修饰白蛋白(UMA)和糖化白蛋白(GA)的肾小管重吸收情况。在输注L - 精氨酸前60分钟以及输注期间采集血清白蛋白和透析尿液样本,将其应用于亲和柱以分离GA和UMA,并测定它们的白蛋白含量。NIDDM患者的血清GA水平高于对照者(P < 0.0001)。与其他两组相比,NIDDM - II组中UMA和GA的排泄均过量(P < 0.0001),且UMA占总白蛋白排泄量的80%。在NIDDM - II组中,UMA的肾小球清除率(2.5±0.16>NIDDM - I组[1.8±0.1]>对照者[1.3±0.1微升/分钟],P < 0.001)和GA的肾小球清除率(1.7±0.13>NIDDM - I组 = 对照者[1.1±0.1微升/分钟],P < 0.001)均高于其他两组。NIDDM - II组中UMA的肾清除率(1.3±0.13微升/分钟)和GA的肾清除率(0.89±0.09微升/分钟)高于对照者(0.27±0.03,0.19±0.02微升/分钟)或NIDDM - I组(0.30±0.03,0.11±0.01微升/分钟)。通过白蛋白肾小球清除率与肾清除率之差评估的NIDDM - II组中UMA的肾小管重吸收(1.1±0.1微升/分钟)低于NIDDM - I组(1.50±0.09微升/分钟),尽管NIDDM - II组中GA和UMA的肾小球清除率有所增加,但NIDDM - II组中GA的肾小管重吸收低于其他两组。总之,NIDDM中的微量白蛋白尿是由于肾小管重吸收能力失代偿导致UMA排泄增加所致,而UMA肾小球清除率的增加超过了这一情况。